{
    "id": 27293,
    "cites": 7,
    "cited_by": 3,
    "reference": [
        "F\u00c3\u0083\u00c2\u00a4tkenheuer, M. Kortepeter, R. Atmar, C. Creech, J. Lundgren, A. Babiker, S. Pett, J. Neaton, T. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, and H. Lane (2020), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Remdesivir for the Treatment of Covid-19--Preliminary Report,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, DOI: 10.1056/NEJMoa2007764.",
        "Cao, B., Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, M. Wei, X. Li, J. Xia, et al. (2020), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Trial of Lopinavir\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cRitonavir in Adults Hospitalized with Severe Covid-19,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 382:1787-1799.",
        "Dunnett, C. (1964), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093New Tables for Multiple Comparisons with a Control,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Biometrics, 20(3), 482-491.",
        "Manski, C. (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Statistical Treatment Rules for Heterogeneous Populations,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 72(4), 221-246.",
        "Manski, C. and A. Tetenov (2016), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Sufficient Trial Size to Inform Clinical Practice,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Proceedings of the National Academy of Sciences, 113(38), 10518-10523.",
        "Manski, C. and A. Tetenov (2019), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Trial Size for Near-Optimal Treatment: Reconsidering MSLT-II,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Statistician, 73(S1), 305-311.",
        "Stoye, J. (2009), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Minimax Regret Treatment Choice with Finite Samples,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Econometrics, 151, 70-81."
    ]
}